CN104784752A - Injectable bone cement with antioxidation characteristic as well as preparation method and application thereof - Google Patents
Injectable bone cement with antioxidation characteristic as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN104784752A CN104784752A CN201510193933.1A CN201510193933A CN104784752A CN 104784752 A CN104784752 A CN 104784752A CN 201510193933 A CN201510193933 A CN 201510193933A CN 104784752 A CN104784752 A CN 104784752A
- Authority
- CN
- China
- Prior art keywords
- bone cement
- phosphate
- beta
- carotene
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002639 bone cement Substances 0.000 title claims abstract description 58
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 39
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 27
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 27
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 27
- 239000011648 beta-carotene Substances 0.000 claims abstract description 27
- 229960002747 betacarotene Drugs 0.000 claims abstract description 27
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000002270 dispersing agent Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000010452 phosphate Substances 0.000 claims abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008367 deionised water Substances 0.000 claims abstract description 8
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 8
- 239000001509 sodium citrate Substances 0.000 claims abstract description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 22
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 14
- 238000007711 solidification Methods 0.000 claims description 11
- 230000008023 solidification Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 235000011132 calcium sulphate Nutrition 0.000 claims description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 239000001175 calcium sulphate Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 3
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 210000002449 bone cell Anatomy 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 10
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000007596 consolidation process Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000011083 cement mortar Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- YOAODOSOQLDRID-UHFFFAOYSA-J dicalcium;hydrogen phosphate;sulfate Chemical compound [Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]S([O-])(=O)=O YOAODOSOQLDRID-UHFFFAOYSA-J 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention discloses injectable bone cement with an antioxidation characteristic as well as a preparation method and application thereof. The bone cement consists of powder and liquid, wherein the powder consists of phosphate, sulfate and beta-carotene powder; the liquid consists of one or more of sodium citrate, sodium hydrogen phosphate and deionized water. The bone cement is prepared by using the preparation method which comprises the following steps: (1) uniformly mixing phosphate, sulfate, beta-carotene powder and a dispersing agent according to a mass ratio, wherein beta-carotene is 0.1-1% of the total mass and the dispersing agent is 0.01-0.3% of the total mass; (2) adding the solidified liquid to stir uniformly, wherein the proportion of the addition of the solidified liquid to the powder mixture prepared in the step (1) is 1.5-2.0 g/mL. The prepared bone cement has the characteristics of being injectable and high in strength, is capable of automatically and rapidly solidifying under physiological environment, and has good bioactivity, antioxidation characteristic and bone cell inducing characteristic.
Description
Technical field
The present invention relates to bone cement, be especially specifically related to a kind of syringeability bone cement with anti-oxidation characteristics and its production and use.
Background technology
The mark of osteoporosis is that bone density reduces, bone strength reduces, and it is the general bone metabolism disorder disease increasing to feature with risk of bone fracture; Wherein senile osteoporosis sickness rate is higher.Osteoporosis and osteoporotic fracture have become the serious public health social problem of worldwide concern, and Chinese existing patients with osteoporosis 9,000 ten thousand, accounts for 7.1% of total population; Along with the process of social senilization, the sickness rate of osteoporosis is still in rising trend, expects the year two thousand fifty will be increased to 2.21 hundred million, and osteoporotic fracture wherein about over half will occur in China.
Osteoporosis be the destruction of bone micro-structure at all, but osseous tissue has normal calcification, and calcium salt and substrate are normal rates, how slowly therefore fall ill, easily cause fracture.At present, clinically for osteoporotic fracture, the main fixing means adopting non-drug, but because the bone mass of patients with osteoporotic bone fracture is poor, be difficult to carry out effective internal fixtion, and fixed position elastic modelling quantity is comparatively large, thus increases the risk of adjacent sections generation refracture.
The topical therapeutic of osteoporosis and osteoporotic fracture is a kind of new technique means.By applying somatomedin and the biomaterial of osteosporosis resistant medicament or promoting bone growing at the position being easy to occur osteoporotic fracture, or directly fill above-mentioned material at fracture site, not only can reach the bone density improving local osteoporotic bone, the object improving bone micro-structure and bio-mechanical property, also avoid the internal fixtion problem of osteoporosis sample.
Apatite bone cement (Calcium phosphate cement, CPC) be a class novel, there is good biocompatibility and bioactive bone renovating material, can solidify voluntarily in physiological conditions, and can according to any plastotype in Cranial defect position also, its hydrated product hydroxyapatite is the host inorganic constituent of skeleton tissue.Also studies have found that, CPC has good biological degradability and bone conductibility, can in human body environment progressively degraded and absorbed being substituted by freshman bone tissue, overcome the deficiency from/bone renovating materials such as allograph bone, acrylic acid bone cement, bioceramic.But along with going deep into of research, conventional CPC has shown some shortcomings part, as very poor in mobility, curing rate is slow, mechanical strength is poor, degradation rate is low, these deficiencies have limited its application at more wide spectrum.At present, modification is carried out to CPC and just becoming one of emphasis of bio-medical material circle research to improve its physics and chemistry and biology performance.
The CPC cured product obtained by tetracalcium phosphate and calcium hydrogen phosphate system, calcium sulfate system is stoichiometric hydroxyapatite (HAP), its calcium-phosphorus ratio (Ca/P) is 1.67, degradable and absorption in vivo, but syringeability is poor, under pressurized condition, there will be solid-liquid separation; In order to improve its injection property, adding surfactant and improving bonding state between powder liquid, the good CPC powder of mobility can be obtained.
Beta-carotene has the title of vitamin a source, is a kind of important human body physiological function active substance.In recent years, about beta-carotene is to the research Showed Very Brisk of human body effect.Large quantity research confirms; many biological functions of beta-carotene and human health have substantial connection; it is at antioxidation, removing toxic substances, anticancer, angiocardiopathy preventing, and the physiological action of preventing and treating cataract and the liver protecting aspect is confirmed more and more and is applied to prevention and treatment of diseases.Research shows, beta-carotene reduces its injury effect to cell by the combination with free radical.
Up to the present, the work carrying out studying and exploring for the syringeability bone cement both combined have not been reported.
Summary of the invention
Technical problem to be solved by this invention is, in order to the defect overcoming existing bone cement poor fluidity, mechanical strength is not suitable for, biocompatibility is to be improved, degradation speed is too slow, and a kind of good flowing properties is provided, mechanical strength is suitable for, good biocompatibility, degradation property are excellent is used for the treatment of syringeability bone cement with anti-oxidation characteristics of osteoporotic fracture and its production and use.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is: a kind of syringeability bone cement with anti-oxidation characteristics, bone cement is made up of powder body and liquid, powder body comprises sulfate, phosphate, dispersant and beta-carotene, and beta-carotene accounts for the 0.1%-1% of bone cement powder body gross mass.
Described liquid is one or more compositions in sodium citrate, dibastic sodium phosphate and deionized water.
Described dispersant is the one or more combination in polyvinylpyrrolidone, Polyethylene Glycol, carboxymethyl cellulose and polyvinyl alcohol, and described dispersant accounts for the 0.01%-0.3% of bone cement powder body gross mass.
Described phosphate is one or more in tetracalcium phosphate, tricalcium phosphate, calcium hydrogen phosphate, and sulfate is one or both compositions in half-H 2 O calcium sulphate and calcium sulfate.
The above-mentioned preparation method with the syringeability bone cement of anti-oxidation characteristics, comprises the steps:
(1) by sulfate, phosphate and beta-carotene powder body and dispersant mix homogeneously in mass ratio, wherein beta-carotene accounts for the 0.1%-1% of powder body gross mass, and dispersant accounts for the 0.01%-0.3% of powder body gross mass;
(2) add the liquid agitation of solidification evenly, powder mixture prepared in the addition of the liquid of solidification and step (1) is than being 1.5g/mL-2.0g/mL.
The liquid of described solidification is deionized water.
The above-mentioned syringeability bone cement with anti-oxidation characteristics, as the purposes in bone renovating material.
The invention has the beneficial effects as follows: injecting bone cement of the present invention has good fluidity, fast solidifying feature, Wicresoft can inject, and solidify voluntarily under physiological environment, hardening time is short, comprcssive strength is close to spongy bone demand, and cured product is mainly hydroxyapatite.
Accompanying drawing explanation
Fig. 1 is the comprcssive strength figure of antioxidation biology active bone cement of the present invention.
Detailed description of the invention
Below in conjunction with the drawings and specific embodiments, the present invention is described in further detail:
The syringeability bone cement with anti-oxidation characteristics of the present invention, bone cement is made up of powder body and liquid, and powder body comprises sulfate, phosphate, dispersant and beta-carotene, and beta-carotene accounts for the 0.1%-1% of bone cement powder body gross mass.
Described liquid is one or more compositions in sodium citrate, dibastic sodium phosphate and deionized water.
Described dispersant is the one or more combination in polyvinylpyrrolidone, Polyethylene Glycol, carboxymethyl cellulose and polyvinyl alcohol, and described dispersant accounts for the 0.01%-0.3% of bone cement powder body gross mass.
Described phosphate is one or more in tetracalcium phosphate, tricalcium phosphate, calcium hydrogen phosphate, and sulfate is one or both compositions in half-H 2 O calcium sulphate and calcium sulfate.
The above-mentioned preparation method with the syringeability bone cement of anti-oxidation characteristics, comprises the steps:
(1) by sulfate, phosphate and beta-carotene powder body and dispersant mix homogeneously in mass ratio, wherein beta-carotene accounts for the 0.1%-1% of powder body gross mass, and dispersant accounts for the 0.01%-0.3% of powder body gross mass;
(2) add the liquid agitation of solidification evenly, powder mixture prepared in the addition of the liquid of solidification and step (1) is than being 1.5g/mL-2.0g/mL.
The liquid of described solidification is deionized water.
The above-mentioned syringeability bone cement with anti-oxidation characteristics, as the purposes in bone renovating material.
The present invention prepares Wicresoft's injecting bone cement, makes it have Bone Defect Repari function, for preventing and treating osteoporotic fracture.Injectable materials, while reparation bone, also can promote new bone formation, thus control osteoporotic fracture; The micropore of bone cement material is conducive to growing into of osteocyte/tissue, thus improves the degradability of material, promotes Bone Defect Repari.
The present invention adds antioxidant beta-carotene, reaches the osseous tissue that prevents from contacting with bone cement and bone surrounding tissue is aging and the old and feeble disease caused; Its metabolite vitamin A has promoting growth of cell ability, has facilitation to the growth of new bone, thus promotes that osseous tissue is grown into.
Described dispersant is that this area is conventional, and consumption is that this area is conventional, and preferably, the consumption of described dispersant is the 0.01%-0.3% accounting for described CPC powder quality.
Mode below by embodiment further illustrates the present invention, but does not therefore limit the present invention among described scope of embodiments.The experimental technique of unreceipted actual conditions in the following example, conventionally and condition.
The syringeability bone cement of embodiment 1-4 antioxidation biology activity and the preparation of slurry thereof:
Bone cement powder is prepared by the tetracalcium phosphate of 1 ︰ 2 and calcium hydrogen phosphate, appropriate other phosphate, sulfate and beta-carotene, dispersant by mol ratio, wherein Beta Carotene Powder quality accounts for 0.1%-1%, and the consumption of dispersant is the 0.01%-0.3% accounting for CPC quality.
In embodiment, the composition of bone cement powder used is in table 1.Four kinds of bone cements all adopt deionized water to be consolidation liquid.
The composition of several bone cement powder of table 1
Note: gross mass is 100%
Embodiment 5 performance test
1, the mensuration of setting time
Cement consistency and coagulation time tester is adopted to measure the setting time of bone cement slurry.
Mixed homogeneously by a certain percentage with consolidation liquid by bone cement powder, high H=10mm made by the cement mortar be in harmonious proportion, and the sample of diameter D=6mm puts into 37 DEG C after the demoulding, solidify, take out at set intervals in 100% humidity environment.During mensuration, be placed in by sample on glass plate and test point is contacted with slurry face, loosen screw suddenly, test point freely sinks to slurry, observes pointer instruction numerical value.Be defined as setting time from be in harmonious proportion powder and sink to slurry to test point and be no more than the time that 1mm experiences.
2, the mensuration of comprcssive strength
Mixed homogeneously by a certain percentage with consolidation liquid by bone cement powder, the cement mortar be in harmonious proportion is put into stainless steel mould and is made high H=12mm, the sample of diameter D=6mm, flattens with the weight of 2kg to drive bubble away as far as possible.Take out the batten after pressing through, put into 37 DEG C, solidify certain hour in 100% humidity environment, two ends polish, and measure comprcssive strength with material mechanical performance universal testing machine, imposed load speed is 1mm/min, often organize data at least three parallel laboratory tests.
3, porosity measurement
Prepare the sample of regular shape and suitable size, put into 37 DEG C of pure water and flood 24h after measuring its diameter D, height H and dry weight M1, weigh after taking out wipe surfaces moisture M2, the quality of water in weightening finish and space, volume shared by it and pore volume.Often organize at least three Duplicate Samples.
4, the mensuration of external degradation performance
This experiment adopts phosphate buffer solution (PBS) to evaluate the degradability of bone cement firming body.By bone cement firming body sample vacuum drying, its first weight (W0) of accurate weighing, record, numbering.Again sample is immersed in PBS and be placed in 37 DEG C, vibrate in the constant temperature oscillation case of rotating speed 100r/min, within every 48 hours, change PBS once, total immersion bubble 12 weeks.Regular taking-up sample, sucks moisture with filter paper, and weigh after vacuum drying (Wt), and observe the metamorphosis of sample.
Weight-loss ratio according to formulae discovery sample below: weight-loss ratio=(W0-Wt)/W0 × 100%, often organizes 3 Duplicate Samples, averages.
5, after degraded, pH value measures
Several bone cement samples of solidification after 24 hours are immersed in SBF respectively, are placed in 37 DEG C, vibrate in the constant temperature oscillation case of rotating speed 100r/min, after 1 hour, 12 hours, 48 hours, 5 days, 7 days, measure the pH value of solution in immersion with pH meter respectively.
Can learn from result, the content of beta-carotene has obvious impact the hardening time on bone cement, beta-carotene add the hardening time extending common calcium sulfate calcium phosphate bone cement; Along with the reduction of content, the setting time of bone cement shortens gradually, the content of beta-carotene 0.1% time hardening time about 15min.
The comprcssive strength of content to firming body of beta-carotene also has certain influence, beta-carotene add the compressive strength reducing common calcium sulfate calcium phosphate bone cement, be about about 2MPa.
Adding of dispersant effectively improves the present situation that apatite bone cement fluidity is poor, injectivity is poor; After being mixed into slurry, viscoelasticity is better, good flowing properties, and adding pressure does not have obvious solid-liquid separation, injectable;
After bone cement solidification prepared by the present invention, through-hole rate is high, can reach more than 20%.
Degradation speed is moderate, degradable about 4% after 24h, within 11 weeks, can reach 60%-70%.The pH of degradation solution between 6.0-6.8, in faintly acid.
The comprcssive strength of gained sample in the corresponding embodiment 1-4 of difference shown in Fig. 1, the comprcssive strength of the active injecting bone cement of the antioxidation biology prepared as seen from the figure is all at more than 2MPa.
On the basis meeting this area general knowledge, above-mentioned each optimum condition, can combination in any, obtains the preferred embodiments of the invention.
Above-described embodiment is only for illustration of technological thought of the present invention and feature, its object is to enable those skilled in the art understand content of the present invention and implement according to this, only can not limit the scope of the claims of the present invention with the present embodiment, namely the equal change done of all disclosed spirit or modification, still drop in the scope of the claims of the present invention.
Claims (7)
1. have a syringeability bone cement for anti-oxidation characteristics, it is characterized in that, bone cement is made up of powder body and liquid, and powder body comprises sulfate, phosphate, dispersant and beta-carotene, and beta-carotene accounts for the 0.1%-1% of bone cement powder body gross mass.
2. the syringeability bone cement with anti-oxidation characteristics according to claim 1, is characterized in that, described liquid is one or more compositions in sodium citrate, dibastic sodium phosphate and deionized water.
3. the syringeability bone cement with anti-oxidation characteristics according to claim 1, it is characterized in that, described dispersant is the one or more combination in polyvinylpyrrolidone, Polyethylene Glycol, carboxymethyl cellulose and polyvinyl alcohol, and described dispersant accounts for the 0.01%-0.3% of bone cement powder body gross mass.
4. the syringeability bone cement with anti-oxidation characteristics according to claim 1, it is characterized in that, described phosphate is one or more in tetracalcium phosphate, tricalcium phosphate, calcium hydrogen phosphate, and sulfate is one or both compositions in half-H 2 O calcium sulphate and calcium sulfate.
5. there is a preparation method for the syringeability bone cement of anti-oxidation characteristics as claimed in claim 1, it is characterized in that, comprise the steps:
(1) by sulfate, phosphate and beta-carotene powder body and dispersant mix homogeneously in mass ratio, wherein beta-carotene accounts for the 0.1%-1% of powder body gross mass, and dispersant accounts for the 0.01%-0.3% of powder body gross mass;
(2) add the liquid agitation of solidification evenly, powder mixture prepared in the addition of the liquid of solidification and step (1) is than being 1.5g/mL-2.0g/mL.
6. the preparation method with the syringeability bone cement of anti-oxidation characteristics according to claim 5, is characterized in that, the liquid of described solidification is deionized water.
7. there is the syringeability bone cement of anti-oxidation characteristics as claimed in claim 1, as the purposes in bone renovating material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510193933.1A CN104784752A (en) | 2015-04-22 | 2015-04-22 | Injectable bone cement with antioxidation characteristic as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510193933.1A CN104784752A (en) | 2015-04-22 | 2015-04-22 | Injectable bone cement with antioxidation characteristic as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104784752A true CN104784752A (en) | 2015-07-22 |
Family
ID=53550229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510193933.1A Pending CN104784752A (en) | 2015-04-22 | 2015-04-22 | Injectable bone cement with antioxidation characteristic as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104784752A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031738A (en) * | 2015-09-09 | 2015-11-11 | 山东明德生物医学工程有限公司 | Weak-exothermic bone cement and preparation method and application |
| CN105396178A (en) * | 2015-11-20 | 2016-03-16 | 山东明德生物医学工程有限公司 | Injectable antibacterial bone cement |
| CN105536070A (en) * | 2016-02-05 | 2016-05-04 | 山东明德生物医学工程有限公司 | Composite bone cement and preparation method thereof |
| CN109125804A (en) * | 2018-10-18 | 2019-01-04 | 暨南大学 | A kind of solidify liquid and the preparation method and application thereof suitable for calcium orthophosphate base bone cement |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090324669A1 (en) * | 2006-07-26 | 2009-12-31 | The Regents Of The University Of California | Osteogenic enhancer composition |
| CN103379923A (en) * | 2010-07-02 | 2013-10-30 | 阿格诺沃医疗保健有限责任公司 | Composition comprising calcium phosphate and sulfate powders and tri-calcium phosphate particles used in the treatment of degenerative bone conditions |
| CN104056305A (en) * | 2014-04-24 | 2014-09-24 | 安泰科技股份有限公司 | Calcium phosphate-based compound self-setting bone repair material and preparation method thereof |
-
2015
- 2015-04-22 CN CN201510193933.1A patent/CN104784752A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090324669A1 (en) * | 2006-07-26 | 2009-12-31 | The Regents Of The University Of California | Osteogenic enhancer composition |
| CN103379923A (en) * | 2010-07-02 | 2013-10-30 | 阿格诺沃医疗保健有限责任公司 | Composition comprising calcium phosphate and sulfate powders and tri-calcium phosphate particles used in the treatment of degenerative bone conditions |
| CN104056305A (en) * | 2014-04-24 | 2014-09-24 | 安泰科技股份有限公司 | Calcium phosphate-based compound self-setting bone repair material and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031738A (en) * | 2015-09-09 | 2015-11-11 | 山东明德生物医学工程有限公司 | Weak-exothermic bone cement and preparation method and application |
| CN105396178A (en) * | 2015-11-20 | 2016-03-16 | 山东明德生物医学工程有限公司 | Injectable antibacterial bone cement |
| CN105536070A (en) * | 2016-02-05 | 2016-05-04 | 山东明德生物医学工程有限公司 | Composite bone cement and preparation method thereof |
| CN109125804A (en) * | 2018-10-18 | 2019-01-04 | 暨南大学 | A kind of solidify liquid and the preparation method and application thereof suitable for calcium orthophosphate base bone cement |
| CN109125804B (en) * | 2018-10-18 | 2021-03-19 | 暨南大学 | Curing liquid suitable for calcium phosphate-based bone cement and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bigi et al. | Effect of added gelatin on the properties of calcium phosphate cement | |
| CN107303397B (en) | A kind of biologically active Injectable compound bone cement and its preparation method and application | |
| CN108635624B (en) | Anti-collapsibility injectable magnesium phosphate-based bone cement | |
| CN100496625C (en) | Calcium sulfate semihydrate group combined self-curing bio-active material, preparation and application thereof | |
| CN104784752A (en) | Injectable bone cement with antioxidation characteristic as well as preparation method and application thereof | |
| KR20070095864A (en) | Resorbable ceramic compositions | |
| CN104853783B (en) | Form composition, monetite cement, implant and the method for correcting Cranial defect of cement | |
| RU2407552C2 (en) | Injectable composite applicable as bone filler | |
| Dai et al. | A novel and injectable strontium-containing hydroxyapatite bone cement for bone substitution: A systematic evaluation | |
| JP2014514065A (en) | Composition comprising Portland cement for use in vertebroplasty | |
| Chang et al. | Development of calcium phosphate/sulfate biphasic cement for vital pulp therapy | |
| CN102049062A (en) | Injectable efficient suspended stable calcium phosphate cement and preparation method and application thereof | |
| JP7483708B2 (en) | Premixed strontium silicate-based biological hydraulic cement paste composition, its manufacturing method and its application | |
| Wang et al. | An injectable porous bioactive magnesium phosphate bone cement foamed with calcium carbonate and citric acid for periodontal bone regeneration | |
| Liu et al. | Design and fabrication of high-performance injectable self-setting trimagnesium phosphate | |
| CN101428152A (en) | Composite self-curing material of dicalcium silicate, preparation and uses thereof | |
| CN104174070B (en) | Strontium calcium composite bone cement and preparation method | |
| CN103263691A (en) | High-biological activity composite material for promoting bone regeneration repair and preparation method thereof | |
| CN106693063B (en) | A kind of anti-collapsibility calcium silicon substrate composite bone cement and its preparation method and application | |
| WO2023216069A1 (en) | Plastic orthopedic composition having erosion resistance | |
| CN107899072A (en) | It is a kind of can pore-forming the composite bone cement that can increase bone hold and its preparation method and application | |
| CN107261214A (en) | A kind of bone renovating material of the acetate containing agarose and preparation method thereof | |
| CN104107455A (en) | Bone cement and slurry thereof | |
| CN1304063C (en) | Self solidified in situ biological activity material, preparation and application | |
| Aberg et al. | In vitro and in vivo evaluation of an injectable premixed calcium phosphate cement; cell viability and immunological response from rat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150722 |
|
| RJ01 | Rejection of invention patent application after publication |